Document |
Document Title |
WO/2022/216900A2 |
The present disclosure relates to novel methods for preparing rapamycin analog compounds, as well as to related intermediates useful in such methods.
|
WO/2022/207699A1 |
The present invention pertains to enzyme-triggered self-reacting arm compounds, chemical intermediates used for preparing such compounds and uses thereof, specifically in prodrug design and conjugation technologies. The present invention...
|
WO/2022/207752A1 |
A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...
|
WO/2022/211498A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
WO/2022/212194A1 |
Compounds of formula (I), wherein the variable substituents are defined herein.
|
WO/2022/211314A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
WO/2022/212815A1 |
Described are 6-aryl quinazolin-4(3H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treat...
|
WO/2022/206964A1 |
Provided are a compound represented by formula (I), a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or co-crystal, or a pharmaceutical composition comprising same, and a use t...
|
WO/2022/211500A1 |
The present invention provides an organic light-emitting device, which comprises, in an emissive layer and/or an electron blocking layer, a compound represented by chemical formula 1, and thus enables efficiency, driving voltage and/or l...
|
WO/2022/204544A1 |
Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula ...
|
WO/2022/199611A1 |
Provided is a heterocycle substituted ketone derivative, the structure of which is as shown in formula (I). Further provided are a pharmaceutically acceptable salt of the derivative, a stereoisomer thereof, a pharmaceutical composition a...
|
WO/2022/200433A1 |
The present invention relates to a group of compounds with a tricyclic core based on imidazo[1,2-b]pyridazine of formula (I) which are inhibitors of HASPIN, whose activity is required for the proliferation of certain tumoral cells, so th...
|
WO/2022/199587A1 |
A pyrimidine heterocyclic compound and an application thereof, in particular, relating to a compound as represented by formula (II) or a pharmaceutically acceptable salt thereof.
|
WO/2022/199576A1 |
A method for preparing midostaurin, the method comprising the following step: reacting a compound as represented by formula N-1 with benzoyl chloride in a pyrrolidone solvent in the presence of a base (such as an inorganic base), thereby...
|
WO/2022/200505A1 |
The present invention relates to novel compounds of general formula (I); wherein X-, Y, and R1 R5 and n have the meanings given in the description and claims, process for preparing these compounds and use thereof.
|
WO/2022/198315A1 |
Methods for treatment of mental and/or mood disorders in a subject are disclosed. The methods comprise administration to a subject in need thereof an effective amount of 2-bromo-LSD and/or a mTOR inhibitor. Also disclosed are pharmaceuti...
|
WO/2022/194399A1 |
The present invention relates to macrocyclic compounds of Formula (I) wherein Ar1, Ar2, R1, R2, R3, R4, and X are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharm...
|
WO/2022/194248A1 |
A CTLA-4 small molecule degradation agent and an application thereof. The CTLA-4 small molecule degradation agent comprises a compound having the structure represented by formula I or a pharmaceutically acceptable salt, an ester, a deute...
|
WO/2022/198112A1 |
Bifunctional compounds, of formula PTM-L-CLM, where the CLM is of formulae al-a4, the PTM f formula PTM-IA and L is a ligand. These compounds act on several diseases via agonism on LRRK2 and cereblon E3 ubiquitin ligase.
|
WO/2022/194976A1 |
Compounds of formula (I) are useful as LRRK2 kinase inhibitors.
|
WO/2022/197761A1 |
The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit f...
|
WO/2022/194096A1 |
A compound represented by formula (I) or a stereoisomer, tautomer or pharmaceutical salt thereof, and use thereof in preparation of a medicament for preventing and/or treating estrogen receptor (ER)-related diseases or disorders.
|
WO/2022/194245A1 |
A pyrimidine-fused cyclic compound having an inhibitory effect on a KRAS gene mutation, or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, a pharmaceutical composition containing the compound, and the use th...
|
WO/2022/195454A1 |
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the...
|
WO/2022/192648A1 |
An active material is orally administered to a mammal substantially daily, which eventually increases the mammal's blood concentration of the active material to an amount effective to control a flea and/or tick infestation of the mammal....
|
WO/2022/192145A1 |
One embodiment of the disclosureis a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat...
|
WO/2022/188729A1 |
The disclosure relates to a KRAS G12D inhibitors of formula (I) or formula (IV), a composition containing the inhibitor and the use thereof.
|
WO/2022/189191A1 |
The invention relates to compounds of formula (I) wherein the variables are as defined in the specification. It also relates to the use of compounds of formula (I) as an agrochemical pesticide; to pesticidal mixtures comprising compounds...
|
WO/2022/189387A1 |
The invention relates to pharmaceutical compounds of formula (I) and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of cyclin-depen...
|
WO/2022/187423A1 |
The present disclosure provides compounds of Formula (I), wherein A, A1, A2, A3, R3, Z and Z1 are as defined in the specification, and the salts and solvates thereof. The present disclosure also relates to uses of the compounds as cerebl...
|
WO/2022/186133A1 |
In agricultural and horticultural crop production, there is still a great amount of damage due to pests and the like. Thus, the present invention addresses the problem of providing a novel agricultural/horticultural pesticide from the vi...
|
WO/2022/184103A1 |
The present invention relates to the field of pharmaceutical chemistry, and relates to a tricyclic compound and a pharmaceutical composition and use thereof. The compound is a compound as represented by formula I, has good PARP7 inhibito...
|
WO/2022/184152A1 |
A compound having HPK1 inhibitory activity as shown in formula (IA) or (IC), and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and use of sam...
|
WO/2022/186221A1 |
[Problem] To provide: a novel tetrahydroisoquinoline (THIQ) alkaloid compound having a macrocyclic structure; an intermediate of the compound; and a method for producing the compound. [Solution] Provided is a compound represented by form...
|
WO/2022/182845A1 |
The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as cancer.
|
WO/2022/177840A1 |
The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising a...
|
WO/2022/174834A1 |
The present application relates to a disaccharide linker, a disaccharide-small molecule drug conjugate and a sugar chain fixed-point antibody-drug conjugate, and a preparation method therefor and the use thereof. The structure of the dis...
|
WO/2022/175747A1 |
Described herein are triazole compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions...
|
WO/2022/175745A1 |
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
|
WO/2022/171265A1 |
The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I).
|
WO/2022/173678A1 |
Provided herein are tetracyclic oxazepinyl compounds useful in the treatment on cancers.
|
WO/2022/171111A1 |
A compound of formula I below as RIP1 kinase inhibitor and uses thereof.
|
WO/2022/171198A1 |
Provided are compounds represented by formula (I), formula (II), formula (III) and formula (IV) as influenza virus replication inhibitors and the use thereof in the preparation of a medicament for preventing or treating influenza.
|
WO/2022/171110A1 |
A compound of formula I below as RIP1 kinase inhibitor and uses thereof.
|
WO/2022/171139A1 |
A compound as represented by formula (1), or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope marker, isomer or prodrug thereof. Also provided are a pharmaceutical composition comprising the compound and...
|
WO/2022/166799A1 |
Provided are a fused tricyclic cyclin-dependent kinase inhibitor, and a preparation method therefor and a pharmaceutical use thereof. In particular, the structure of the fused tricyclic cyclin-dependent kinase inhibitor is shown in formu...
|
WO/2022/166749A1 |
Disclosed are a triheterocyclic compound, a preparation method therefor, and an application thereof. Specifically, provided is a triheterocyclic compound as represented by formula IA or a pharmaceutically acceptable salt thereof. The tri...
|
WO/2022/169948A1 |
Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and m...
|
WO/2022/166991A1 |
An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.
|
WO/2022/169755A1 |
The present application discloses novel compounds of formula (I), pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a co...
|